氟氧头孢联合磷霉素治疗抗菌药物耐药高流行地区新生儿脓毒症
新生儿脓毒症每年致多达68万婴儿死亡,在耐药高发的中低收入国家,WHO推荐的氨苄西林联合庆大霉素经验方案常遇耐药。本研究用16臂剂量范围中空纤维感染模型(HFIM)和棋盘法检测氟氧头孢联合磷霉素,结果显示该联合在杀菌和防止磷霉素耐药出现方面具协同作用;氟氧头孢单药可杀死氟氧头孢MIC≤0.5 mg/L的3/3株至无菌,而氟氧头孢MIC≥8 mg/L的3/3株单药均未杀死、联合杀死其中2/3。
要点
- 氟氧头孢联合磷霉素在HFIM和棋盘法中显示杀菌与抑制磷霉素耐药的协同作用。
- 氟氧头孢MIC≤0.5 mg/L的3/3株被氟氧头孢单药杀至无菌。
- 氟氧头孢MIC≥8 mg/L的3/3株单药未杀死,联合杀死2/3株。
核心结论
- 数据提示氟氧头孢联合磷霉素可能成为耐药高发中低收入国家新生儿脓毒症经验治疗的有效协同方案。
- HFIM结果需进一步在临床试验中评估氟氧头孢联合磷霉素。
研究设计与样本
- 采用16臂剂量范围中空纤维感染模型(HFIM)实验和棋盘法检测评估氟氧头孢联合磷霉素。
- 进一步用临床相关方案在HFIM中评估6株氟氧头孢/磷霉素MIC范围不同的肠杆菌目菌株。
主要发现
- HFIM实验输出的药代动力学/药效学建模及棋盘法数据表明该方案在杀菌和防止磷霉素耐药出现方面具协同作用。
- 氟氧头孢MIC≤0.5 mg/L的3/3株被氟氧头孢单药杀至无菌。
- 氟氧头孢MIC≥8 mg/L的3/3株未被磷霉素或氟氧头孢单药杀死,其中2/3株被两药联合杀死。
局限性
- HFIM结果需进一步在临床试验中评估氟氧头孢联合磷霉素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neonatal sepsis is a serious bacterial infection of neonates, globally killing up to 680 000 babies annually. It is frequently complicated by antimicrobial resistance, particularly in low- and middle-income country (LMIC) settings with widespread resistance to the WHO's recommended empirical regimen of ampicillin and gentamicin. OBJECTIVES: We assessed the utility of flomoxef and fosfomycin as a potential alternative empirical regimen for neonatal sepsis in these settings. METHODS: We studied the combination in a 16-arm dose-ranged hollow-fibre infection model (HFIM) experiment and chequerboard assays. We further assessed the combination using clinically relevant regimens in the HFIM with six Enterobacterales strains with a range of flomoxef/fosfomycin MICs. RESULTS: Pharmacokinetic/pharmacodynamic modelling of the HFIM experimental output, along with data from chequerboard assays, indicated synergy of this regimen in terms of bacterial killing and prevention of emergence of fosfomycin resistance. Flomoxef monotherapy was sufficient to kill 3/3 strains with flomoxef MICs ≤0.5 mg/L to sterility. Three of three strains with flomoxef MICs ≥8 mg/L were not killed by fosfomycin or flomoxef monotherapy; 2/3 of these were killed with the combination of the two agents. CONCLUSIONS: These data suggest that flomoxef/fosfomycin could be an efficacious and synergistic regimen for the empirical treatment of neonatal sepsis in LMIC settings with prevalent antimicrobial resistance. Our HFIM results warrant further assessment of the flomoxef/fosfomycin combination in clinical trials.
引用
- Darlow CA, Farrington N, Johnson A, et al. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. J Antimicrob Chemother. 2022. PMID: 35170719. doi:10.1093/jac/dkac038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。